祥生医疗(688358) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was CNY 165,154,528.52, representing a year-on-year increase of 64.55%[5] - The net profit attributable to shareholders was CNY 52,513,874.14, reflecting a growth of 111.31% compared to the same period last year[6] - Basic earnings per share (EPS) stood at CNY 0.47, up by 113.64% from the previous year[6] - Total operating revenue for Q1 2023 reached RMB 165,154,528.52, a 64.6% increase from RMB 100,367,467.51 in Q1 2022[22] - Net profit for Q1 2023 was RMB 52,513,874.14, representing a 111.1% increase compared to RMB 24,852,007.66 in Q1 2022[23] - The company reported a total profit of RMB 59,674,856.98 for Q1 2023, an increase from RMB 29,011,776.30 in Q1 2022[23] Cash Flow and Liquidity - The net cash flow from operating activities reached CNY 3,297,962.45, an increase of 133.51% year-on-year[6] - Cash flow from operating activities generated a net amount of RMB 3,297,962.45, a significant improvement from a net outflow of RMB 9,842,847.19 in Q1 2022[26] - Cash and cash equivalents at the end of Q1 2023 totaled RMB 476,375,439.25, down from RMB 734,839,296.15 at the end of Q1 2022[27] - Investment activities generated a net cash inflow of RMB 35,595,811.20 in Q1 2023, compared to RMB 307,397,052.00 in Q1 2022[27] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,591,043,073.39, a 5.09% increase from the end of the previous year[6] - The company's total equity as of March 31, 2023, was CNY 1,367,393,741.24, up from CNY 1,313,508,192.90, marking an increase of approximately 4.1%[19] - The total current liabilities rose to CNY 212,505,799.94, compared to CNY 188,470,568.81 at the end of 2022, reflecting an increase of about 12.7%[18] - The total liabilities increased to CNY 223,649,332.15 from CNY 200,418,411.27, reflecting an increase of about 11.6%[19] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 5,354[13] - The top shareholder, Wuxi Xiangsheng Investment Co., Ltd., holds 40.46% of the shares, totaling 45,360,000 shares[13] Research and Development - Research and development (R&D) expenses totaled CNY 19,931,113.52, accounting for 12.07% of operating revenue, a decrease of 6.83 percentage points[6] - Research and development expenses for Q1 2023 were RMB 19,931,113.52, slightly up from RMB 18,967,543.27 in Q1 2022[22] Other Financial Metrics - The company experienced a 902.82% increase in financial expenses, mainly due to foreign exchange losses[11] - The company reported a foreign exchange loss of RMB 5,789,980.73 in Q1 2023, compared to a loss of RMB 1,209,622.83 in Q1 2022[27] - Accounts receivable increased by 128.36%, primarily due to the growth in domestic and international sales revenue[10] - Accounts receivable increased significantly to CNY 213,565,566.53 from CNY 93,521,760.48, representing a growth of approximately 128%[17] - The company's inventory decreased to CNY 161,833,169.93 from CNY 196,957,143.80, a decline of approximately 17.8%[17] - The non-current assets totaled CNY 178,752,164.59, slightly up from CNY 175,100,762.63, indicating a growth of about 1.5%[18] - The company reported a significant increase in other non-current assets to CNY 8,411,230.63 from CNY 5,500,476.00, representing a growth of approximately 52.1%[18] - The company's retained earnings rose to CNY 294,240,893.63 from CNY 241,727,019.49, an increase of approximately 21.7%[19]